Table 2.
Relative levels of gene expression in the samples expressed as the fold-change relative to the healthy control (2-∆∆Ct). (+) up-regulation, (−) down-regulation, nc: no change
| Genes | Endometrial hyperplasia | Grade 1 EC | Grade 2 EC | Grade 3 EC |
|---|---|---|---|---|
| CCL2 | nc | 4.42 | 2,53 | nc |
| CCL17 | 6.94 | +36.37 | +17.80 | 8.58 |
| CD1a | nc | +24.48 | nc | nc |
| CD4 | +5.31 | +8.88 | +3.98 | 5.3 |
| CD8b | +3.3 | +24.6 | −10.18 | nc |
| CD68 | nc | +3.31 | +3.08 | +5.87 |
| CD206 | nc | +2.87 | +2.33 | +4.24 |
| CTLA4 | nc | +10.11 | +16.78 | 15.73 |
| CX3CL1 | nc | +7.98 | +6.56 | +5.81 |
| FoxP3 | nc | +24.68 | +36.91 | +25 |
| Galectin-9 | 2,57 | +4.65 | +3,88 | nc |
| IFNγ | nc | +43.8 | nc | nc |
| IL1β | +7.6 | +9,45 | +27.95 | +101.91 |
| IL6 | +17.45 | +17.37 | +12.94 | +29.46 |
| IL10 | nc | +45.65 | +45.35 | 41.76 |
| IL12 | +8.15 | +83.8 | +30 | nc |
| NCAM1 | −22.46 | −17.01 | −10.08 | −12.26 |
| PD-1 | nc | +15.33 | +79.67 | 59.99 |
| PD-L1 | nc | +43.70 | +284 | 50.16 |
| PD-L2 | nc | nc | +22.15 | 49.12 |
| TIM-3 | nc | +3,69 | +2,61 | +3,99 |